Syntrix Biosystems, Inc.

Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer

Role: collaborator

SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer

Role: collaborator

SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial

Role: collaborator

SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

Role: lead

Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

Role: lead

Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

Role: lead

SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer

Role: collaborator

A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

Role: collaborator

A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Role: collaborator

Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis

Role: lead

A Randomized Study Investigating Oral Desmetramadol Dose Proportionality and Food Effect In Normal Human Subjects

Role: lead

Omnitram Safety and Efficacy in the Treatment of Diabetic Neuropathy

Role: lead

Aminopterin Pharmacokinetic Study In Moderate to Severe Psoriasis

Role: lead

Omnitram Pharmacokinetic and Analgesic Study Following CY2D6 Inhibition With Paroxetine In Healthy Volunteers

Role: lead

Aminopterin Dose Finding Treatment for Methotrexate-Naïve Rheumatoid Arthritis

Role: lead

Omnitram Pharmacokinetic Study In Healthy Volunteers

Role: lead